Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: hotlinktuna who wrote (58083)	3/26/2007 10:17:26 AM
From: bluezuu	Read Replies (1) \| Respond to of 59879

RHGP.OB -- Check this out for a China Play. Trading at 3.12. Just did .15/share in Q4. They forecast another strong qtr as well. -------------------------------------------------- biz.yahoo.com Stronger Revenue and Margins Boost Renhuang Pharmaceutical's First Quarter 2007 Earnings Well Beyond Projections Tuesday March 20, 6:30 am ET Quarterly Net Income Quadrupled Year Over Year and Exceeded That of Entire Six Month Period May 1 - Oct. 31, 2006 Highlights: -- A record quarterly net income of US$5.50 million, up 35% from US$4.23 million for the 6 month period ending October 31, 2006 and up more than 400% from a year ago quarter at US$1.07 million for the "Old Renhuang" -- Quarterly revenues of US$10.6 million, 12% higher than a year ago at US$9.4 million for the "Old Renhuang" -- Net profit margin reached 52%, a record high for the Company -- Earnings per share were US$0.157 for the quarter versus US$0.121 for the six month period ending October 31, 2006 HARBIN, China--(BUSINESS WIRE)--Renhuang Pharmaceuticals, Inc. (or "the Company", Stock symbol: RHGP.OB), a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products in the People's Republic of China (PRC), filed its quarterly report 10Q for the three month period November 1, 2006 - January 31, 2007 and announced the results for the quarter, which is the first quarter of the Company's 2007 fiscal year. For the three months ended January 31, 2007, the Company generated a record quarterly net income of US$5.50 million. This is a 35% increase over the total net income of US$4.23 million for the entire six month period ending October 31, 2006 and 415% higher compared to the net income of US$1.07 million for the same quarter of last year. The record results were primarily driven by sales expansion, seasonal strength, and better product mix with more sales of higher margin products. Reduced costs in advertising, research and development also contributed to the year-over-year increase in earnings. Net profit margin reached 52% compared to 35% for the six month period from May 1 - October 31, 2006 and 11% for the same quarter of the prior year. It is the highest quarterly net profit margin ever achieved by the Company. Basic earnings per common share for the quarter were US$0.157 compared to US$0.121 for the entire six month period ending Oct. 31, 2006. The number of shares issued and outstanding as of the date of the report was 35,000,181. The strong sales of US$10.6 million for the quarter represent a 12% increase from the US$9.4 million for the same quarter of the prior year. The sales consist of 51% from Acanthopanax-base products, 18% from Shark Power Health Care products, and 31% from Traditional Medicine products. Given the fact that the Company only started the current operations as a public company from May 1, 2006, a financial projection based only on the current and the prior year results may not be a good indication of the Company's future performance. Caution should be exercised when making year over year comparisons as prior year results are for "Old Renhuang" which was a non-public company. The financial comparison and projection will be more indicative after the Company has conducted its current operations for a few more periods. "Renhuang Pharmaceuticals delivered record quarterly earnings, driven by seasonal strength, increased sales, and improved product mix," said Renhuang's Chairman and Chief Executive Officer Mr. Li, Shaoming. "Our quarterly net earnings more than quadrupled compared to the prior year quarter and are even substantially higher than the solid results we reported recently for the entire six month period ending October 31, 2006. This is a remarkable achievement of our hard working staff and outstanding management team, especially as we are a young publicly listed company." Further commenting on the outlook for the next quarter, Mr. Li said, "We expect the seasonal strength to continue and we are confident in delivering solid results for another quarter."